Pfizer's Celebrex Patents Upheld
Posted on: Thursday, 22 March 2007, 09:01 CDT
A US district court in New Jersey has upheld Pfizer's patents for anti-inflammatory drug Celebrex against generics manufacturer Teva Pharmaceuticals.
The Israeli-based company had argued that the patents are invalid because prior inventions made the technology "obvious" and because Celebrex was covered by an earlier patent. However, the court ruled that Pfizer's patents on Celebrex capsules in 100 mg, 200 mg, and 400 mg dose strengths are valid and enforceable. Teva plans to appeal this decision.
The decision prohibits Teva from launching a competitor drug in the US until December 2015. Celebrex is the world's top-selling arthritis drug, and its sales totaled $1.57 billion in the US in 2006.
Source: Datamonitor
Related Articles
- Research & Markets: Par Pharmaceutical Boosted Its Position in the US Market Through the Purchase of a Number of Drugs From Teva and IVAX
- Eisai Sues Teva Over Alzheimer's Drug Patent
- PCMA: Extending Prescription-Drug Patents Raises Serious Health Care Cost and Quality Questions
- Generic Drug Makers Taking More Aggressive Approach Against Branded Drug Patents
- Generic Drug Maker Teva to Buy Rival in Multibillion-Dollar Deal
- Cancer Drug Patent ; Biotech Company Aims for Slice of Pounds 1bn Market
- Brazil Warns of Breaking AIDS Drug Patents
- Supreme Court to Hear Drug Patent Dispute
- Celebrex Drug Linked to Heart Attacks
- Pfizer Finds Heart Risk With Celebrex; Drug in Same Class As Vioxx
 |
 |
User Comments (0)
RSS Feeds